13F-HR filed by Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 32 holding rows worth $970,993,636.
- Accession
- 0000950123-23-008184
- Filer
- CIK 1703031
- Filed
- 2023-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2023
A holdings report, 32 entries on the cover page, a total value of $970,993,636 stated on the cover page (in dollars after the unit check, H1), rows summing to $970,993,637 with VALUE read as dollars as filed, 13F file number 028-18477. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBain Capital Life Sciences Partners, LP 028-18476
- included managerBain Capital Life Sciences Fund, L.P. 028-18478
- included managerBC SW, LP 028-20270
- included managerBain Capital Life Sciences Investors II, LLC 028-20816
- included managerBain Capital Life Sciences Fund II, L.P. 028-20814
- included managerBCLS II Investco (GP), LLC 028-22976
- included managerBCLS II Investco, LP 028-22978
- included managerBain Capital Life Sciences III General Partner, LLC 028-22975
- included managerBain Capital Life Sciences Fund III, L.P. 028-22979
- included managerBain Capital Life Sciences Opportunities III GP, LLC 028-22968
- included managerBain Capital Life Sciences Opportunities III, LP 028-22966
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NUVALENT INC COM | 670703107 | Stock | 3,577,267 | $150,853,349 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 10,473,913 | $124,534,826 | dollars as filed | |
| SPRINGWORKS THERAPEUTICS INC | 85205L107 | COM | 3,081,307 | $80,791,870 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 4,868,784 | $73,713,390 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 1,332,548 | $59,165,131 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 2,305,558 | $41,546,155 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 11,622,598 | $37,134,201 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 3,400,000 | $35,258,000 | dollars as filed | |
| NATERA INC COM | 632307104 | Stock | 700,197 | $34,071,586 | dollars as filed | |
| DYNAVAX TECHNOLOGIES CORP | 268158201 | COM NEW | 2,415,000 | $31,201,800 | dollars as filed | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 15,960,588 | $30,963,541 | dollars as filed | |
| ARCUTIS BIOTHERAPEUTICS INC | 03969K108 | COM | 3,000,000 | $28,590,000 | dollars as filed | |
| Mersana Therapeutics Inc | 59045L106 | Common Stock | 8,663,673 | $28,503,484 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 2,500,000 | $27,375,000 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 2,000,000 | $25,820,000 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 5,701,926 | $20,070,780 | dollars as filed | |
| EQRX INC | 26886C107 | COM | 10,003,573 | $18,606,646 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 1,822,883 | $18,210,601 | dollars as filed | |
| SOLID BIOSCIENCES INC | 83422E204 | COMMON STOCK | 3,130,422 | $16,403,411 | dollars as filed | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 1,431,058 | $15,541,290 | dollars as filed | |
| 2SEVENTY BIO INC COMMON STOCK | 901384107 | Stock | 1,408,901 | $14,258,078 | dollars as filed | |
| ATEA PHARMACEUTICALS INC | 04683R106 | COMMON STOCK | 2,485,638 | $9,296,286 | dollars as filed | |
| RAPID MICRO BIOSYSTEMS INC | 75340L104 | CLASS A COM | 8,434,560 | $8,434,560 | dollars as filed | |
| NAUTILUS BIOTECHNOLOGY INC | 63909J108 | COM | 2,000,000 | $7,740,000 | dollars as filed | |
| Xilio Therapeutics Inc. | 98422T100 | COM | 2,805,413 | $7,350,182 | dollars as filed | |
| SYROS PHARMACEUTICALS INC | 87184Q206 | COM NEW | 2,124,694 | $6,692,786 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 1,921,790 | $6,380,343 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 1,642,210 | $4,516,078 | dollars as filed | |
| THIRD HARMONIC BIO INC | 88427A107 | COM | 640,631 | $3,081,435 | dollars as filed | |
| CARA THERAPEUTICS INC | 140755109 | COM | 934,898 | $2,645,761 | dollars as filed | |
| INVIVYD INC | 00534A102 | COMMON STOCK | 1,937,207 | $2,034,067 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV-27 | N62509117 | WTS | 100,000 | $209,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-23-008184 | this filing | 2023-08-14 | acceptance time not in the bulk data set |